Recent Updates — PEN

Penumbra reported third-quarter revenue of $410.1 million, up 15.6% year-over-year, driven by a 18.1% increase in global thrombectomy sales to $279.2 million and a 10.8% rise in embolization and access revenue to $131.0 million. Net income was $42.3 million, or $1.07 per diluted share, compared to $45.9 million in the prior-year period. The company cited $7.1 million in acquisition-related expenses associated with its pending merger with Boston Scientific Corporation as a factor in operating costs. Penumbra will not provide full-year 2026 guidance or host an earnings call due to the pending transaction. Penumbra is a medical device company specializing in thrombectomy technologies for treating ischemic stroke and venous thromboembolism.

Penumbra, Inc. reported second quarter 2026 financial results with revenue of $390.0 million, a 14.9% increase year-over-year. Global thrombectomy revenue rose 12.5% to $259.0 million, while embolization and access revenue grew 20.0% to $131.1 million. The company achieved a gross profit margin of 67.9%, up 1.9 percentage points, and reported net income of $34.8 million. Operating expenses totaled $223.9 million, including $6.9 million in acquisition-related costs associated with its pending merger with Boston Scientific Corporation. Due to the pending acquisition, Penumbra did not provide full-year financial guidance or host a conference call. Penumbra is a medical device company specializing in thrombectomy technologies for treating ischemic stroke and other vascular conditions.